BofA lowered the firm’s price target on Inspire Medical to $180 from $355 and keeps a Buy rating on the shares. While the firm contends that current medtech multiples have “likely discounted too much for GLP-1 concerns,” unless expectations change on GLP-1 weight-loss drugs, medtech likely will trade at some discount compared to recent history and the firm lowering some targets in the group to reflect this new discount as well as higher interest rates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on INSP:
- Inspire Medical price target lowered to $300 from $380 at Mizuho
- Inspire Medical initiated with a Market Perform at Leerink
- Inspire Medical price target lowered to $260 from $340 at Truist
- Inspire Medical Systems, Inc. to Report Third Quarter 2023 Financial Results on November 7, 2023
- Inspire Medical Systems, Inc. Announces Events at International Surgical Sleep Society and American Academy of Otolaryngology – Head and Neck Surgery Meetings